Altimmune, Inc.
ALT
$5.33
$0.224.21%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.00K | 20.00K | 20.00K | 20.00K | 52.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.00K | 20.00K | 20.00K | 20.00K | 52.00K |
| Cost of Revenue | 67.80M | 72.65M | 76.57M | 82.23M | 79.35M |
| Gross Profit | -67.78M | -72.63M | -76.55M | -82.21M | -79.30M |
| SG&A Expenses | 22.68M | 21.74M | 21.65M | 20.97M | 20.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 90.48M | 94.39M | 98.21M | 103.19M | 99.56M |
| Operating Income | -90.46M | -94.37M | -98.19M | -103.17M | -99.51M |
| Income Before Tax | -84.60M | -88.43M | -90.92M | -95.06M | -103.52M |
| Income Tax Expenses | -681.00K | -681.00K | -681.00K | -- | -- |
| Earnings from Continuing Operations | -83.92 | -87.75 | -90.24 | -95.06 | -103.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.92M | -87.75M | -90.24M | -95.06M | -103.52M |
| EBIT | -90.46M | -94.37M | -98.19M | -103.17M | -99.51M |
| EBITDA | -90.34M | -94.24M | -98.03M | -102.93M | -99.19M |
| EPS Basic | -1.07 | -1.18 | -1.25 | -1.34 | -1.55 |
| Normalized Basic EPS | -0.67 | -0.74 | -0.79 | -0.84 | -0.84 |
| EPS Diluted | -1.07 | -1.18 | -1.25 | -1.34 | -1.55 |
| Normalized Diluted EPS | -0.67 | -0.74 | -0.79 | -0.84 | -0.84 |
| Average Basic Shares Outstanding | 317.70M | 299.37M | 288.82M | 284.07M | 271.25M |
| Average Diluted Shares Outstanding | 317.70M | 299.37M | 288.82M | 284.07M | 271.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |